Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 171-177 , July 2010

Improving Radiation Conformality in the Treatment of Non–Small-Cell Lung Cancer

  • Joe Y. Chang, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Joe Y. Chang, MD, PhD, Division of Radiation Oncology, Unit 97, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030
    • ,
  • James D. Cox, MD

References 

  1. Curran W, Scott C, Langer C, et al. Long term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable NSCLC. Proc Am Soc Clin Oncol. 2003;22:621a
  2. Socinski M, Rosenman J, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B non-small cell lung carcinoma. Cancer. 2001;92:1213–1223
  3. Schild S, McGinnis W, Graham D, et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1106–1111
  4. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117–125
  5. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma clinical outcome in 245 subjects in a Japanese multi-institutional study. Cancer. 2004;101:1623–1631
  6. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–1431
  7. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839
  8. Chang JY, Balter P, Dong L, et al. Stereotactic body radiation therapy in centrally, superiorly located stage I or isolated recurrent NSCLC. Int J Radiat Oncol Biol Phys. 2008;72:976-071
  9. Chang JY, Roth JA. Stereotactic body radiation therapy for stage I NSCLC. Thorac Surg Clin. 2007;17:251–259
  10. Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:94–102
  11. Liao ZX, Komaki RR, Thames HD, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;76:775–781
  12. Chang JY, Liu H, Komaki R. Intensity-modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Curr Oncol Rep. 2005;7:255–259
  13. Cox JD, Chang JY, Liao Z, et al. Acute esophageal reactions from proton beam therapy and concurrent chemotherapy for NSCLC: Reduction in incidence and severity despite higher doses. J Thorac Oncol. 2007;2:S449
  14. Chang JY, Komaki R, Wen HY, et al. Toxicity and patterns of failure of dose-escalated proton therapy in early-stage medically inoperable non-small cell lung cancer. J Thorac Oncol. 2009;4:S525
  15. Chang JY, Komaki R, Bucci MK, et al. Failure patterns and toxicity of concurrent proton therapy and chemotherapy for stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75:S446
  16. Chang JY, Dong L, Liu H, et al. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol. 2008;3:177–186
  17. Engelsman M, Rietzel E, Kooy HM. Four-dimensional proton treatment planning. Int J Radiat Oncol Biol Phys. 2006;64:1589–1595
  18. Kang Y, Zhang X, Chang JY, et al. 4D proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys. 2007;67:906–914
  19. Hui Z, Zhang X, Starkschall G, et al. Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys. 2008;72:1385–1395
  20. Nehmeh S, Erdi Y, Pan T, et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys. 2004;31:3179–3186
  21. Liu H, Balter P, Tutt T, et al. Assessing respiration-induced tumor motion and internal target volume using 4-D CT for radiation therapy of lung cancer. Int J Radiat Oncol Biol Phys. 2007;68:531–540
  22. Ezhil M, Vedam S, Balter P, et al. Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography. Radiol Oncol. 2009;4:4
  23. Vedam S, Dong L, Zhang J, et al. Impact of respiration-induced tumor motion uncertainties on adaptive treatment delivery strategies: A comparison through repeat 4-D CT imaging. Int J Radiat Oncol Biol Phys. 2006;66:614
  24. Britton K, Starkschall G, Pan T, et al. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography (4-D CT). Int J Radiat Oncol Biol Phys. 2007;68:1036–1046
  25. Rosenzweig KE, Hanley J, Mah D, et al. The deep inspiration breath-hold technique in the treatment of inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;48:81–87
  26. Ramsey C, Scaperoth D, Arwood D, et al. Clinical efficacy of respiratory gated conformal radiation therapy. Med Dosim. 1999;24:115–119
  27. Hoogeman M, Prévost JB, Nuyttens J, et al. Clinical accuracy of the respiratory tumor tracking system of the cyberknife: Assessment by analysis of log files. Int J Radiat Oncol Biol Phys. 2009;74:297–303
  28. Suh Y, Sawant A, Venkat R, et al. Four-dimensional IMRT treatment planning using a DMLC motion-tracking algorithm. Phys Med Biol. 2009;54:3821–3835
  29. Klopp A, Chang JY, Liu H, et al. Intra-thoracic patterns of failure for non-small cell lung cancer (NSCLC) with PET/CT-defined target delineation. Int J Radiat Oncol Biol Phys. 2007;69:1409–1416
  30. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551–560
  31. Galvin JM, De Neve W. Intensity modulating and other radiation therapy devices for dose painting. J Clin Oncol. 2007;25:924–930
  32. Bowen SR, Flynn RT, Bentzen SM, et al. On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Phys Med Biol. 2009;54:1483–1501
  33. Bentzen SM. Radiation therapy: Intensity-modulated, image-guided, biologically optimized and evidence based. Radiother Oncol. 2004;77:227–230
  34. Schwarz M, Van der Geer J, Van Herk M, et al. Impact of geometrical uncertainties on 3-D CRT and IMRT dose distributions for lung cancer treatment. Int J Radiat Oncol Biol Phys. 2006;65:1260–1269
  35. Bortfeld T, Jokivarsi K, Goitein M, et al. Effects of intra-fraction motion on IMRT dose delivery: Statistical analysis and simulation. Phys Med Biol. 2002;47:2203–2220
  36. Liu H. The physics aspects of intensity-modulated radiation therapy for lung cancers. In:  Cox JD,  Chang JY,  Komaki R editor. Image-Guided Radiotherapy of Lung Cancer. New York, NY: Taylor and Francis Group; 2008;p. 91–112
  37. Murshed H, Liu H, Liao Z, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1258–1267
  38. Liu H, Wang X, Dong L, et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1268–1279
  39. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1087–1096
  40. Bush DA, Slater JD, Shin BB, et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004;126:1198–1203
  41. Hata M, Tokuuye K, Kagei K, et al. Hypofractionated high-dose proton beam therapy for stage I non-small cell lung cancer: Preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys. 2007;68:786–793
  42. Zhang X, Li Y, Pan X, et al. Intensity-modulated proton therapy reduces normal tissue doses compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small cell lung cancer: A virtual clinical study. Int J Radiat Oncol Biol Phys. Aug 4, 2009;[Epub ahead of print]
  43. Seco J, Robertson D, Trofimov A, et al. Breathing interplay effects during proton beam scanning: Simulation and statistical analysis. Phys Med Biol. 2009;54:283–294

 Supported in part by grant NCI RO1-CA74043 and NIH PO1-CA 021239.

PII: S1053-4296(10)00013-5

doi: 10.1016/j.semradonc.2010.01.005

Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 171-177 , July 2010

Article Tools

* Image Usage & Resolution